Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML

BACKGROUND: CPX-351 (United States: Vyxeos(®); Europe: Vyxeos(®) Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved by the US FDA and the EMA for the treatment of adults with newly diagnosed therapy-related acute myeloid leuke...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortes, Jorge E., Lin, Tara L., Uy, Geoffrey L., Ryan, Robert J., Faderl, Stefan, Lancet, Jeffrey E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276472/
https://www.ncbi.nlm.nih.gov/pubmed/34256819
http://dx.doi.org/10.1186/s13045-021-01119-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276472/
https://www.ncbi.nlm.nih.gov/pubmed/34256819
http://dx.doi.org/10.1186/s13045-021-01119-w

Ejemplares similares